Aspira Pathlab & Diagnostics Ltd
₹ 58.5
-5.00%
22 May
- close price
About
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services[1]
Key Points
- Market Cap ₹ 60.2 Cr.
- Current Price ₹ 58.5
- High / Low ₹ 107 / 25.0
- Stock P/E 29.1
- Book Value ₹ 11.9
- Dividend Yield 0.00 %
- ROCE 17.2 %
- ROE 23.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is expected to give good quarter
- Debtor days have improved from 53.3 to 39.0 days.
- Company's working capital requirements have reduced from 46.0 days to 27.9 days
Cons
- Stock is trading at 4.93 times its book value
- Promoter holding is low: 18.4%
- Company has a low return on equity of -2.99% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -17.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00 | -0.00 | -0.00 | 0.76 | 4.36 | 7.64 | 8.42 | 15.21 | 19.54 | 14.46 | 13.20 | 22.00 | |
| 0.02 | 0.14 | 0.23 | 3.34 | 8.24 | 10.88 | 10.25 | 11.69 | 13.16 | 12.86 | 14.38 | 18.47 | |
| Operating Profit | -0.02 | -0.14 | -0.23 | -2.58 | -3.88 | -3.24 | -1.83 | 3.52 | 6.38 | 1.60 | -1.18 | 3.53 |
| OPM % | -339.47% | -88.99% | -42.41% | -21.73% | 23.14% | 32.65% | 11.07% | -8.94% | 16.05% | |||
| 0.02 | 0.21 | 0.32 | 0.31 | 0.22 | 0.25 | 0.29 | 0.20 | 0.09 | 0.32 | 0.42 | 0.39 | |
| Interest | -0.00 | -0.00 | 0.05 | 0.26 | 0.80 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.35 |
| Depreciation | -0.00 | -0.00 | -0.00 | 0.20 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 |
| Profit before tax | -0.00 | 0.07 | 0.04 | -2.73 | -5.58 | -5.18 | -4.21 | 1.39 | 4.46 | -0.09 | -2.67 | 2.08 |
| Tax % | 57.14% | 25.00% | -0.00% | -0.00% | -0.00% | 0.71% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | |
| -0.00 | 0.02 | 0.03 | -2.72 | -5.58 | -5.18 | -4.24 | 1.38 | 4.46 | -0.09 | -2.67 | 2.07 | |
| EPS in Rs | -0.00 | 0.09 | 0.13 | -5.24 | -10.75 | -6.32 | -4.56 | 1.34 | 4.33 | -0.09 | -2.59 | 2.01 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 4% |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 20% |
| 3 Years: | -23% |
| TTM: | 178% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 3% |
| 1 Year: | 89% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -3% |
| Last Year: | 24% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 2.25 | 2.25 | 5.19 | 5.19 | 8.19 | 9.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 |
| Reserves | 0.19 | 1.36 | 1.39 | 0.72 | -4.86 | -7.93 | -10.42 | -6.91 | -2.43 | -2.47 | -5.08 | 1.92 |
| -0.00 | -0.00 | 2.62 | 7.29 | 11.36 | 12.52 | 13.80 | 7.01 | 8.85 | 8.24 | 7.71 | 3.20 | |
| 0.03 | 0.21 | 0.03 | 1.66 | 0.84 | 2.02 | 1.67 | 1.39 | 1.42 | 1.28 | 1.79 | 2.10 | |
| Total Liabilities | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.51 |
| -0.00 | -0.00 | 0.04 | 7.79 | 7.91 | 8.90 | 8.70 | 7.75 | 9.57 | 8.01 | 6.79 | 6.53 | |
| CWIP | -0.00 | -0.00 | -0.00 | 0.25 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.13 |
| 0.62 | 3.82 | 6.25 | 6.82 | 4.62 | 5.90 | 5.64 | 4.03 | 8.56 | 9.33 | 7.92 | 10.85 | |
| Total Assets | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.51 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.37 | -1.29 | -4.81 | -3.39 | -1.87 | 5.67 | 2.03 | -0.01 | 1.05 | 1.88 | ||
| 0.08 | -0.02 | -10.14 | -0.77 | -1.97 | 0.24 | -0.09 | -0.51 | 0.16 | 0.14 | 0.07 | ||
| -0.06 | 2.64 | 8.91 | 6.52 | 3.35 | 1.27 | -2.17 | -1.35 | -0.94 | -0.95 | -0.99 | ||
| Net Cash Flow | -0.00 | 2.25 | -2.52 | 0.94 | -2.00 | -0.35 | 3.41 | 0.17 | -0.79 | 0.24 | 0.95 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43.22 | 29.30 | 38.22 | 26.01 | 40.80 | 83.87 | 59.07 | 61.94 | 38.99 | |||
| Inventory Days | 312.86 | 103.88 | 45.22 | 51.36 | 51.35 | 46.50 | 58.40 | 62.69 | 50.31 | |||
| Days Payable | 730.00 | 64.58 | 46.84 | 73.37 | 91.60 | 70.91 | 51.10 | 101.70 | 73.00 | |||
| Cash Conversion Cycle | -373.92 | 68.61 | 36.60 | 4.00 | 0.55 | 59.46 | 66.37 | 22.93 | 16.30 | |||
| Working Capital Days | -465.86 | 1.67 | -2.39 | -5.20 | 36.24 | 81.44 | 65.63 | 44.52 | 27.87 | |||
| ROCE % | -0.00% | 1.82% | -25.39% | -38.41% | -34.49% | -25.15% | 19.77% | 35.65% | 2.01% | -15.87% | 17.15% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 May - Newspaper Advertisement for the Standalone & Consolidated Financial Results as on March 31, 2025
-
100% Acquisition Of Stake And Strike Off Of Aspira DNA Diagnostics Gujarat LLP
16 May - Aspira to acquire 100% stake in associate Aspira DNA Diagnostics Gujarat LLP and strike it off.
-
Re-Appointment Of Dr. Pankaj Shah (DIN: 02836324) As Managing Director & CEO Subject To The Members Approval For A Period Of Three (3) Years
16 May - Re-appointment of Dr. Pankaj Shah as MD & CEO from Aug 2025 to Jul 2028.
-
Intimation Of Appointment Of Secretarial Auditor And Internal Auditor
16 May - Appointed Secretarial Auditor for 5 years and Internal Auditor for FY 2025-26.
-
Integrated Filing (Financial)
16 May - Audited FY25 results approved; MD re-appointed; secretarial and internal auditors appointed; postal ballot planned.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
Company is in the business of running, owning, managing and administering Diagnostics Centers in Mumbai